Could an arthritis drug ease Sjögren's symptoms?
NCT ID NCT01782235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether tocilizumab, a drug that blocks inflammation, can help people with primary Sjögren's syndrome—an autoimmune disease causing dry eyes, dry mouth, pain, and fatigue. Researchers gave 110 participants either tocilizumab or a placebo to see if it could reduce disease activity. The goal was to find a new treatment option for this chronic condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tocilizumab (a drug that blocks IL-6, a protein involved in inflammation)
What this could lead to
If successful, this could point toward a new treatment option to control disease activity and improve symptoms in people with primary Sjögren's syndrome.
What could go wrong
This is a completed Phase 2/3 trial, but results may not show significant benefit over placebo. Tocilizumab also carries risks like infection, and not all patients may respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME (PSS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67098, France